ARIAD Pharma (ARIA) Tops Q3 EPS by 3c

ARIAD Pharma (NASDAQ: ARIA) reported Q3 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $16.5 million.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• The LGL Group (LGL) Misses Q2 EPS by 8c